Imatinib (STI-571, Gleevec) is a prototype Abl kinase inhibitor that has been shown to reduce the production of proinflammatory cytokines (TNFα, IL-8, and IL-1β) and alleviate lung injury in a mouse model of ALI.314 A series of case reports suggest that Abl kinase inhibitors may reduce vascular permeability in specific patients. This evidence concerns the gene TNF and acute respiratory distress syndrome.